Cargando…
The Medicinal Chemistry of Imidazotetrazine Prodrugs
Temozolomide (TMZ) is the standard first line treatment for malignant glioma, reaching “blockbuster” status in 2010, yet it remains the only drug in its class. The main constraints on the clinical effectiveness of TMZ therapy are its requirement for active DNA mismatch repair (MMR) proteins for acti...
Autores principales: | Moody, Catherine L., Wheelhouse, Richard T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113733/ https://www.ncbi.nlm.nih.gov/pubmed/25014631 http://dx.doi.org/10.3390/ph7070797 |
Ejemplares similares
-
Antitumour imidazotetrazines: past, present… and future?
por: Stevens, Malcolm F. G., et al.
Publicado: (2023) -
Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.
por: Goddard, C., et al.
Publicado: (1985) -
Tunable Stability of Imidazotetrazines Leads to a
Potent Compound for Glioblastoma
por: Svec, Riley L., et al.
Publicado: (2018) -
C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage
por: Yang, Zhikuan, et al.
Publicado: (2019) -
Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects
por: Krečmerová, Marcela, et al.
Publicado: (2022)